| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Sorafenib | CCLE | pan-cancer | AAC | -0.086 | 0.06 |
| mRNA | FH535 | GDSC1000 | pan-cancer | AAC | -0.064 | 0.06 |
| mRNA | EX-527 | GDSC1000 | pan-cancer | AAC | 0.064 | 0.06 |
| mRNA | CI-1040 | GDSC1000 | pan-cancer | AAC | -0.06 | 0.06 |
| mRNA | BRD-K14844214 | CTRPv2 | pan-cancer | AAC | -0.072 | 0.06 |
| mRNA | WZ4002 | CTRPv2 | pan-cancer | AAC | -0.08 | 0.06 |
| mRNA | bid1870 | gCSI | pan-cancer | AAC | 0.099 | 0.06 |
| mRNA | JQ-1:navitoclax (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.062 | 0.07 |
| mRNA | UNC0638 | GDSC1000 | pan-cancer | AAC | 0.054 | 0.07 |
| mRNA | CIL70 | CTRPv2 | pan-cancer | AAC | 0.085 | 0.07 |